No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Chongqing Taiji Industry (Group) Co.,Ltd operates as a pharmaceutical enterprise, conducting business both within China and across international markets. The company focuses on the research, development, manufacturing, and distribution of traditional Chinese medicines and various health products. Its offerings are available in a wide array of formats, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, and powders. The product line addresses a comprehensive range of health conditions and therapeutic areas. These include disorders of the digestive and respiratory systems, cardiovascular and cerebrovascular ailments, pediatric and gynecological health, systemic anti-infective agents and antibiotics, pain relief medications, orthopedic treatments, remedies for colds and coughs, and drugs for the endocrine and nervous systems. The firm's headquarters are situated in Chongqing, China.
www.taiji.comNo one on the platform currently holds 600129.SS.
No tracked institution reports a position in 600129.SS as of their last filing.
No one on the platform has traded 600129.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.1% | — | — | — | ||
| Rev. Growth % | -15.6% | -1.4% | ||||
| Profit Margin % | 1.2% | 1.0% | 1.7% | |||
| Free Cash Flow Margin % | 0.6% | -0.6% | -2.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.9B | +3.7% | $0.50 | $0.50–$0.50 | — | 1 |
| 2027 | $11.4B | +4.8% | $0.93 | $0.93–$0.93 | — | 1 |
| 2028 | $11.8B | +3.8% | $1.19 | $1.19–$1.19 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-04-24 | $0.45 | $0.13 | -71.1% |
| 2025-03-28 | $0.13 | $-0.93 | -815.4% |
| 2024-10-24 | $0.40 | $0.09 | -77.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600129.SSChongqing Taiji Industry(Group) Co.,Ltd | $13.37 | -0.30% | $7.4B | — |
| 002099.SZZhejiang Hisoar Pharmaceutical Co., Ltd. | $5.35 | -0.19% | $8.7B | — |
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.31 | -0.00% | $7.7B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.26 | +0.74% | $9.9B | — |
| 300026.SZTianjin Chase Sun Pharmaceutical Co., Ltd. Class A |
| $3.19 |
| +0.31% |
| $9.6B |
| — |
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. | $19.12 | -0.78% | $10.8B | — |
| 600812.SSNorth China Pharmaceutical Company Ltd. | $4.55 | -0.87% | $7.8B | — |
Source: Financial Modeling Prep · peers by sector/industry